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pathogen replication may
putting the unvaccinated
can be transmitted throug1. An evolutionary hypothesis for pathogen virulence
Why are pathogens virulent?1 Why would they run the risk of
killing their host when, in doing so, they lose their ongoing source
of transmission to newhosts? Some evolutionary biologists believe
that the answer to this questionwill make it possible to design vac-
cines and other control measures that, in the event of eradication
being impossible, drive the pathogen towards lower virulence [1,2].
One answer to this question is that virulence is a mistake by the
pathogen—an ultimately maladaptative outcome that occasionally
happens when a pathogen accidentally ends up in an abnormal
host environment, or when a virulent mutant has a transient
competitive advantage within a host (‘short-sighted, or dead-end
evolution’) [3]. An alternative (but not mutually exclusive [4]) idea
is that the level of pathogen virulence observed in nature is a well-
adapted outcome of both positive and negative selective forces
acting on virulence. Under this hypothesis, it is reckoned that to
balance the ﬁtness cost to the pathogen of host death, there must
also be a virulence-related advantage to the pathogen’s ﬁtness. This
is the so-called ‘virulence trade-off hypothesis’.
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gramme, PO Box 230, Kiliﬁ 80108, Kenya.
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1 Throughout this paper, we strictly deﬁne virulence as the ﬁtness cost that the
parasite causes the host. Thismay be throughmortality, ormorbidity-related reduc-
tion in fertility or fecundity. We sometimes use morbidity as a surrogate measure
of virulence.
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gens are virulent (i.e., they damage their host) is that they need to extract
er to compete for transmission to new hosts, and this resource extraction
escribe our studies in malaria that test and support this idea. We go on to
xacerbate selection for virulence and therefore that vaccines that reduce
ct for more virulent pathogens, eroding the beneﬁts of vaccination and
ater risk. We suggest that in disease contexts where wild-type parasites
cinated hosts, evolutionary outcomes need to be considered.
© 2008 Elsevier Ltd.
Of all the explanations for virulence, the trade-off hypothesis
has received most attention and a large body of theory has been
derived from it. Yet it is poorly supported by data. Herewe describe
our studies in malaria parasites, the causative agents of a disease
of global importance, in which we have comprehensively explored
the trade-off hypothesis.Webegin by summarising our experimen-
tal tests in a laboratory mouse-malaria system of the assumptions
underlying the trade-off theory. We then ask whether the rodent
Open access under CC BY license.data are relevant to malaria parasites in their human setting. Next,
we use the trade-off theory to predict what the impactmight be on
the evolution of the pathogen’s virulence if malaria vaccines went
into widespread use. Finally, we summarise an experimental evo-
lution study to test our prediction that enhanced immunity would
select formore virulent parasites. Together, thiswork has led us to a
deeper understanding of whymalaria still kills its host despitemil-
lenia of coevolution, and what might happen when disease control
campaigns change the level of population immunity, e.g., enhance
it using vaccines, or reduce it using bednets and vector control.
1.1. The trade-off hypothesis and its assumptions
Under the trade-off hypothesis, it is assumed that there are
both ﬁtness beneﬁts and costs associated with virulence. The cost
is assumed to be host death because, for most pathogens, trans-
mission stops when the host dies. The beneﬁts associated with
virulence are assumed tobeproductionofmore transmission forms
per unit time, and/or increased persistence in a live host. However,
the beneﬁts of higher transmissibility and persistence only accrue
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the transmissibility and duration of infection curves have to be less than linear (i.e.
if the host survives: if it dies, transmission immediately ceases,
thereby directly reducing the pathogen’s ﬁtness. The pathogen
is thus playing a perilous game, attempting to maximise trans-
missibility and infection length while also keeping its host alive.
Pathogens with the highest ﬁtness are those with an intermediate
level of virulence which balances these opposing contributions to
ﬁtness (Fig. 1).
1.2. Evidence from myxomatosis
Although the trade-off idea was mooted by medical epidemiol-
ogists early in the 20th century [5] and much later by theoretical
biologists [6,7], it was Anderson and May’s [8] analysis of the prin-
ciple using a real-life example which really focussed thinking. The
myxoma virus was extremely virulent when released into rabbit
populations in Australia and Britain in the early 1950s, but over
the next decade, the virus evolved to an intermediate and sta-
ble level of virulence [9,10]. Using data from Fenner and Ratcliffe
[11] which showed that viral strains that caused more host death
were also those capable of generating longer infections (Fig. 2a),
Anderson and May [8] showed that maximum ﬁtness of the virus
occurred at an intermediate level of virulence. Thiswas because the
more virulent strains produced longer infections in the absence of
host death, but death occurred more often in these strains. In their
analysis they assumed that transmissibility was constant, i.e., the
trade-off was generated exclusively by the relationship between
virulence and infection length. Similarly, using the data of Mead-
Briggs and Vaughan [12] which show higher transmissibility in the
more virulent strains (except at very high levels, Fig. 2b), Massad
[13] showed that maximum pathogen ﬁtness was reached at inter-
mediate levels of virulence. Thus either the virulence–infection
length relationship or the virulence–transmissibility relationship,
or the combination of the two (Fig. 2c) could explain the observedion) to pathogen ﬁtness. The ﬁtness beneﬁts associated with virulence are higher
ost mortality which shortens the infection. The rate of transmission and length of
) multiply together to give the total lifetime transmission of the pathogen from the
the negative and positive effects on virulence are combined in this way. Note that
x) in order to produce an intermediate optimum virulence.
evolution of themyxoma virus from extreme virulence to interme-
diate virulence through time.
2. Malaria
Inspired by the myxomatosis example, and conscious of the
lack of relevant data in medically important pathogens, we set
out to explore whether this trade-off was operating in a major
pathogen of humans—Plasmodium. The causative agent of the
most pathogenic form of human malaria, Plasmodium falciparum,
replicates rapidly within its host, as do many viral, bacterial,
and other protozoal pathogens. Unlike viruses and bacteria, how-
ever, the malaria parasite has separate transmission stages called
gametocytes. Gametocytes, the sexual form of the parasite, are
differentiated from the asexual, replicating blood-stage forms.
Gametocytesdonot themselves replicate, andare seenat lowdensi-
ties in thebloodstream.Butas theyare theonly forms that survive in
themosquitovector, thepathogenmustproduce theminorder tobe
transmitted. Moreover, mosquitoes only feed on live hosts. In hosts
that survive, immunity clears parasites. Thus, on the face of it, the
necessary ingredients for the trade-offmodel are present: themost
evolutionarily successful parasite is one which maximises trans-
mission stage production while avoiding host death and immune
clearance.
2.1. Data from mouse malaria
We began by testing the assumptions of the trade-off hypoth-
esis using the mouse-malaria model, Plasmodium chabaudi, as an
experimentalmodel. Using parasite clones obtained from their nat-
ural host in the wild [14] and then passaged for a short period
in laboratory mice, we infected groups of inbred mice and mea-
sured the transmissibility, virulence andpersistence of these clones
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1960s, strains of the virus that were less virulent than the original were found to be
of these strains showed positive, curvilinear relationships with infectivity to ﬂeas/
laboratory rabbits. Using either of these relationships, and keeping the other one c
the case when both vary, as shown in panel C. The predicted ﬁtness function match
the most prevalent strains (grey bars) in the population were those of intermediate
resistance [81,82]. Note that the very low infectivity of the highly virulent strain is no
curve that saturated at 60% would too. Following Anderson and May [8], assumed
the daily transmission rate to uninfected rabbits approximately equal to infectivity,
and the genetic (i.e., across-clone) relationships among these
traits [15–17]. Transmissibility was measured as the number of
gametocytes per unit time: it was further measured as the pro-
portion of mosquitoes that became infected after being allowed
to take a blood-meal from an infected mouse. Persistence was
measured by the time it took to clear an infection to below a
threshold value. Virulence was, for ethical and logistical reasons,
measured not by mortality but by morbidity, viz., maximum level
of anaemia or weight loss experienced by the host during the
infection: these are positive indicators of the probability of host
death. We also measured the maximum asexual parasite den-
sity reached during the infection as an indicator of the parasite’s
degree of exploitation of the host. In malaria, this is a useful trait
through which virulence–transmission–persistence relationships
(hereafter V–T–P) can be examined since parasite density is amajor
underlying cause of all three traits: asexual replication is directly
responsible for disease pathology, production of gametocytes and
for maintenance of the infection.
Our experiments showed that clones that had higher levels
of virulence also had higher transmissibility (both production of
gametocytes and infectivity tomosquitoes) and cleared their infec-
tions more slowly in the absence of host death (Fig. 3) [15–18].
Virulent parasites were also those that generated highest parasite
densities and thus exploitedmore of the host’s resources (red cells).
Thus the V–T–P relationships assumed by the trade-off hypoth-
esis, and the parasite genetic basis for them, were supported in
this experimental model. Furthermore, if the host died, the total
amount of gametocytes produced during the infection (i.e., the
potential transmission) was less than if the host lived (Fig. 3e) thus
demonstrating a clear cost of hostmortality to the parasite’s ﬁtness
[19]. This result, however, was not repeated in a similar study [17]
despite similar levels of mortality and gametocyte production in
both experiments. Further and larger experiments are required to
determine the magnitude of the cost of host death to parasite ﬁt-
ness. The ﬁndings described above were also broadly supported, at
least at the phenotypic level, in another experimental system, the
avian malaria, Plasmodium gallinaceum infecting chickens [20].
We found theV–T–P relationships also to be positivewhenmea-
sured indifferenthost genotypes [19,21], host sexes [22], after serial
passage [18,19,22], aftermosquito passage [22,23] and, importantly
(see below), in hosts with different levels of acquired immunity
[16,22]. Thus clones that were genetically more virulent, transmis-
sible andpersistentwere consistently so, across a range of extrinsic,
host-derived factors.ased into a rabbit population of Australia and Britain in the early 1950s. By the mid-
ating in the populations (graded I–V in increasing order of virulence). The virulence
uitoes [12] (panel A) and the length of infection [11] (panel B) when measured in
nt, gives maximum ﬁtness at an intermediate level of virulence [8,13]: this is also
distribution of strains observed in Australia after a decade (1959–1969) [80] where
ence, a situation which lasted for some time until the host evolved higher levels of
ssary to generate an intermediate virulence optimum: a transmissibility–virulence
of other parameters were a background mortality rate of 0.011/day and values of
.1–0.6 transmissions per infected rabbit per day.
In nature, malaria infections are frequently composed of sev-
eral genetically distinct strains of parasites. This introduces into
the relatively simple scenario described above the question of
whether the more virulent parasites are still more productive (i.e.,
ﬁt) than their less virulent counterparts when they are compet-
ing in the same host. Theoreticians have envisaged a range of
possible outcomes of this competition, and hence effects on vir-
ulence evolution (reviewed in [24]). Experimental data using the
P. chabaudi model, generally indicate that more virulent clones
have a competitive advantage: they are able to competitively sup-
press or even exclude less virulent clones during the acute phase
of mixed-clone infections [25,26]. The competitive outcome is
reﬂected in relative gametocyte production of the two compet-
ing strains [27] and hence transmission to mosquitoes [25,28].
This result appears to be qualitatively robust to host genotype
[29] and host immune status [30,31]. Thus, the transmission and
persistence advantages of virulence accrue even in mixed infec-
tions.
Important to the argument that follows, in the mouse model,
immunity acted to reduce all three traits – transmissibility, vir-
ulence, and persistence – in line with that expected from the
relationships among these traits in naı¨ve hosts. Also, clones broadly
retained their rankings for virulence and other traits across naı¨ve
and immune hosts (Fig. 3). In other words, the parasite lines that
replicated well, transmitted faster, lasted longer and caused more
morbidity when infecting naı¨ve hosts, also did so in semi-immune
hosts but just at a lower level.
2.2. Data from human malaria
Do theV–T–P relationshipsweobserved inmice apply to human
malaria? Unfortunately there are not adequate data to properly
assess this, and thereprobablyneverwill be. This is becausewecan-
not, for both logistical and ethical reasons, measure the virulence
of a panel of distinct human malaria strains in groups of human
hosts. However, two types of data which represent the phenotypic
relationships among these traits are qualitatively consistent with
the positive genetic relationships we observed in the laboratory
mouse.
The ﬁrst type of data comes from a longitudinal cross-sectional
population survey in Nigeria (the Garki project) [32]. The data from
this are summarised in the form of plots of average values for each
age-class of V, T and P (measured bymortality rates, average game-
tocyte density while infected, and duration of infection for each
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malar
site geFig. 3. Virulence–transmissibility–persistence relationships in the mouse model of
with one parasite clone: thus a line ﬁtted to the points would represent the para
symbols indicatemicemade semi-immune by previous infection and drug clearance. Viru
the infection. It was shown to positively relate to transmissibility as measured by daily
during the peak of gametocyte production (panel B). Recovery rate (panel C), which is inv
declined after peak parasitaemia and was negatively related to virulence, as expected. V
of host exploitation. Clones broadly retained their rankings for all traits when infecting n
the four traits used here.) In the experiments described in panels A–D, very few mice die
experiment using less resistant host genotypes, mortality was high (23%) and was show
shown in panel E. Data were reproduced with permission from Mackinnon et al. [19] and
new infection, respectively) against average asexual densities, an
indicator of the degree of host exploitation by the parasite (Fig. 4).
Across theage-spectrum,all three traits increasedwithexploitation
levels, consistent with those assumed by the trade-off hypothesis
and observed in rodent and avian malarias.
However, two important caveats apply to these human malaria
data regarding their relevance to the trade-off hypothesis. The ﬁrst
is that parasite genetics is averaged out in these relationships (each
age-group is assumed to be infected by the whole range of parasite
genotypes in the population). Second, the observed relationships
are undoubtedly driven by age-acquired immunity. Thus theseia, P. chabaudi. Each point is the average value of groups of mice (n=5–10) infected
netic relationship among the traits. Filled symbols indicate naı¨ve mice and open
lencewasmeasured as themouse’sminimum red blood cell density reached during
average gametocyte density (panel A), and infectivity to mosquitoes on 2–4 days
ersely related to infection length, was measured as the rate at which the infection
irulence was positively related to maximum parasitaemia (panel D), an indicator
aı¨ve vs. immunised mice (Pearson correlations across treatments of 0.59–0.66 for
d and so a virulence cost to transmission was not observable. However, in another
n to severely reduce the total number of gametocytes produced by the infection,
Mackinnon and Read [16].
curves, tight as they are, do not directly yield the parasite’s genet-
ically encoded ﬁtness beneﬁts and costs of virulence as assumed
by the model (Fig. 1), and seen in myxomatosis (Fig. 2) and rodent
malaria (Fig. 3). However, the Garki data are certainly not inconsis-
tent with the model.
A second source of data on V–T–P relationships is the series of
infections of human patients with P. falciparum malaria in order
to treat their neurosyphilis. Several laboratory-maintained strains
were used to treat hundreds of patients, and their courses of asex-
ual parasite densities, gametocyte densities, infection lengths, and
morbidity (fever) were recorded for each infection for as long as 18
C46 M.J. Mackinnon et al. / VaccinFig. 4. Relationships between level of host exploitation, transmissibility, persis-
tence, and virulence (mortality) in humanmalaria in the ﬁeld. Datawere taken from
a longitudinal study in Nigeria in the 1970s (the Garki project, [32]). Host exploita-
tion is on the x-axis and is represented by average asexual parasite density. Each
symbol represents an average for a group of people from the same age-group mea-
sured in eight surveys, and decreases in size with age. Transmissibility (panel A) is
represented by gametocyte density, and then converted to infectivity (dotted line,
right axis) using logistic regression ﬁtted to data from experimentalmosquito infec-
tivity data from the literature (data not shown). Persistence (panel B) is represented
by infection length estimated from consecutive 10-week surveys [83] and adjusted
for superinfections to lengths of individual infections using the method described
by Dietz et al. [84]. All-cause mortality rates (panel C) are shown as closed symbols:
these are due to other factors as well as malaria, and include all the malaria infec-
tions that occur in a host per year, i.e., including superinfections. The open symbols
represent the values of mortality assuming that 25% of all deaths under the age of 9
years, and 1% in older categories, are due tomalaria: these values are representative
of studies where these proportions have been estimated, albeit with considerable
uncertainty [40].
months, thus giving data relevant to V–T–P relationships [33,34].
It was found that infections among malaria-naı¨ve patients that
reached higher maximum parasite densities, or had faster growth
ratesduring theearly stageof the infection, alsopersisted for longer,
and caused higher levels of morbidity than infections that reached
lowermaximumdensities (Mackinnon, unpublished results). How-
ever, as for the ﬁeld studies described above, because few parasitee 26S (2008) C42–C52
strains were used, these relationships could not be attributed to
parasite genetics. Thus we still do not have a basis on which to crit-
ically evaluate the assumptions of the trade-off model for human
malaria.
It must also be noted, however, that there are various pieces
of evidence to indicate the potential for virulence evolution in
human malaria in response to changing selection pressures. These
are as follows: there appears to be a parasite genetic basis to viru-
lence, replication rate and perhaps transmissibility in P. falciparum
(reviewed in [35]); there is some variability in virulence main-
tained in nature [36,37]; and there appears to be a link between
intrinsic replication rate and virulence in P. falciparum [38] (but
see [39]). We recognise that there are many environmental and
genetic factors relating to both the vertebrate and mosquito hosts
that contribute much variability to the V–T–P relationships in
human malaria. What matters, however, to the direction of viru-
lence evolution is whether, when averaged over all this variability,
the parasite-encoded V–T–P relationships are qualitatively similar
to that assumed by the theory (Fig. 1).
Our experimental work with P. chabaudi clearly demonstrates
ﬁtness beneﬁts to virulence (transmissibility, persistence, and com-
petitive ability). These are thus factors that promote the evolution
of increased virulence. What factors balance these, preventing the
evolutionof extremelyvirulentmalaria?The trade-offmodel envis-
ages the balancing selective pressure to arise through host death.
But in the ﬁeld, the majority of malaria infections do not end in
death. Determining what the case fatality rate is for malaria in
endemic regions is difﬁcult, so that estimates are controversial, but
the probability of a single infection leading to death is certainly less
than 10% andprobably less than 1%, perhaps even <0.1% [40]. Is such
a low risk of death a sufﬁcient cost of virulence to offset the ﬁtness
beneﬁts we have seen? (Note that even a small amount of mortal-
ity may be sufﬁcient to counterbalance a fairly ﬂat transmissibility
curve.) To work this out deﬁnitively, we would need to determine
both the transmission beneﬁts and transmission costs associated
with higher death rates. The population-wide case fatality rate is
not a good indicator of whether evolution of high virulence is being
constrained by host death because it does not directly reﬂect these
transmission gains and losses. We would also need to take account
of the variable amount of transmission from hosts with different
levels of immunity. Thus the optimum virulence at endemic equi-
librium will not only depend on the shape of the virulence–ﬁtness
curve, but also on the parasite’s productivity (total transmission
per infection lifetime) in each host type, and the abundance of each
host type [41–45].
Data from the Garki project help to illustrate this last point.
Mortality rates are much higher in children, especially very young
children, where they are two orders of magnitude higher than in
adults (Fig. 4c). But it is also these younger (non-immune) groups
that have the capacity to generate high gametocyte densities and
persistent infections (Fig. 4a and b). As Fig. 5 shows, this is the
group that contributes most (20-fold more than adults) to the par-
asite’s total transmission population, but also suffers the highest
virulence and hence cost to transmission. Thus one might plau-
sibly argue that it is the youngest children, who transmit most
but die most often, that have the most ‘weight’ in determining
the optimum level of virulence for the population. Moreover, more
virulent parasites could be maintained in the population by semi-
immune, transmitting adults, because they are less likely to kill
their hosts. Thus if looked at from the host’s point of view, one
could say that theyoungchildrenarepaying the cost of adult immu-
nity. This raises the question we now turn to: how will virulence
evolution be altered when a greater proportion of the parasites
are facing immune hosts, as would occur following widespread
vaccination?
M.J. Mackinnon et al. / VaccinFig. 5. Theexpected amount of total transmission fromhosts indifferent age-classes
in the Garki project based on the data shown in Fig. 4 gives some indication of
the parasite’s relative ﬁtness in different host types. Total transmission (black bars)
was calculated as infectivity multiplied by vectorial capacity (the expected number
of infectious bites to new hosts that result from a mosquito feeding on one host,
infected or not, assumed to have a value of 8 here) divided by the expected infection
length. Infection length here is the reciprocal of all-causemortality rate (Fig. 4c) plus
recovery rate (the inverse of individual infection length, Fig. 4b). We use the length
of an individual parasite infection in this calculation because we are interested in
the relative transmission, or ﬁtness, of an individual parasite strain rather than the
total transmission from a group of coinfecting strains occupying the same host. By
contrast, mortality rate in this calculation is all-cause mortality because individual
parasite genotypes suffer from themortality caused by coinfecting parasites as well
as that caused by themselves. To illustrate the cost of host death on the parasite’s
total lifetime productivity, we have performed the same calculation as above but
assuming that none of the all-cause mortality is due to malaria (see Fig. 4 legend)
(white bars). The different-sized symbols above the bars correspond to those for the
different age-classes in Fig. 4.
3. The vaccination theory
3.1. The principle
Before going on to describe the principle of our vaccination
theory, we deﬁne two terms which will be used in the following
discussion: these are intrinsic and realised virulence. Realised viru-
lence is the virulence that would be observed in a host at a given
level (any level) of host defence. Intrinsic virulence is the virulence
that would be observed if the parasite was infecting a naı¨ve host:
in a better-defended host, for the same level of intrinsic virulence,
the realised virulence would be lower. We need intrinsic virulence
as a common reference in order to study changes in virulence in
populations of hosts with mixed levels of defence.
If there are intrinsic biological links between the V–T–P traits
that cover the whole spectrum of host defence, the parasite in
semi-immune hosts is subject to the same ﬁtness trade-off as
proposed for naı¨ve hosts (Fig. 1). The only difference is that the
realised cost of virulence, host death, is lower in immune hosts
than the realised cost in naı¨ve hosts. This means that in semi-
immune hosts, the parasite, in order to achieve higher effective
replication rate, transmission and persistence, can afford a higher
level of intrinsic virulence without paying the cost of host death.
In other words, parasites with high virulence can ‘get away with
it’ in a semi-immune host. Therefore intrinsic virulence should
evolve to be higher in populations with higher levels of immunity
than in populations of naı¨ve hosts [4,43,46–50]. In our model the
amount by which it does so in a population consisting entirely of
immune hosts, relative to that for a completely naı¨ve population,
is the exact same amount by which immunity decreases realised
virulence over intrinsic virulence. This principle is illustrated ine 26S (2008) C42–C52 C47
Fig. 6. Note that under the assumptions of our model, this princi-
ple would apply to any pathogenwhere the trade-off holds, and for
any form of host resistance (genetically innate, naturally acquired,
or vaccine-induced) that operates to reduce parasite virulence, e.g.,
via reduced parasite growth rates or anti-toxin effects [43,51].
3.2. Application to asexual-stage vaccines in malaria
Thedata frommice andhumans strongly indicate that inmalaria
the common factor underlying the V–T–P relationships is asexual
parasite density.We reasoned, therefore, that any controlmeasures
that brought about a reduction in asexual parasite densities would
bring about evolution for increased intrinsic virulence because of
its consequences to transmissibility, persistence and host mortal-
ity [43]. This would include anti-asexual-stage vaccines and drugs
whichwere imperfect or ‘leaky’, i.e., thatdidnot completelyprevent
or clear infections, respectively. If this evolutionwere tohappen, the
unprotected (e.g., unvaccinated) people in the population would
then be exposed to a more virulent parasite and their risk of death
would be higher than before.
On the other hand, it might be argued, the vaccine, if used
widely, would protect many more people from disease so that
the population-wide reduction in mortality may well outweigh
the increased mortality among the unvaccinated few. Further, the
vaccine would reduce the force of infection through its effect on
transmissibility, thus conferring an extra beneﬁt to the population
through herd immunity [52]. This would further relieve the nat-
ural selection pressure on the parasite’s virulence from naturally
acquired immunity. It would also reduce the incidence of multiple
infections: all of these effects are generally considered to be ben-
eﬁcial. Thus, as is often the case in vaccination programmes, even
without evolution, the beneﬁts to the majority of the population
have to be weighed against the risk to a few individuals.
Therefore, to determine the beneﬁt to the whole population of
vaccination allowing for an evolutionary response in the parasite’s
virulence, we modelled the case of virulence evolution under an
imperfect asexual-stage malaria vaccine incorporating the feed-
backs between the epidemiology (force of infection) and parasite
evolution [43]. Parameter values were chosen to mimic an area of
high year-round malaria transmission such as Tanzania. As pre-
dicted, the parasite evolved higher virulence under vaccination so
that the case fatality rate amongst unvaccinated naı¨ve hosts was
higher than if evolution had not occurred. Moreover, the total mor-
tality across thewhole populationwas also higher, especiallywhen
the vaccine was given to a moderate fraction of the population.
Thus all the expected beneﬁts of vaccination were eroded by para-
site evolution, and the situation was worse at intermediate levels
of vaccine coverage (Fig. 7).
3.3. Other types of vaccines and coinfection
We also modelled other types of vaccines or devices that block
infection (e.g., liver stage vaccines), or stop it transmitting from
humans to mosquitoes, (e.g., bednets), but that do not act directly
on the asexual-stage parasites and hence on the V–T–P relation-
ships. These control measures were predicted to have no impact,
or as we explain below, could even lead to a decrease in viru-
lence [43]. Thus, priority should be given to control measures that
prevent pathogens from entering or leaving the host rather than
measures that directly target the infection itself. Inmalaria, the for-
merwould include bednets, vector control, and sporozoite and liver
stage vaccines (unless they also reduce multiplication rates); the
latter includes asexual-stage vaccines, anti-toxin vaccines and drug
use. Thus, in the face of a large potential for pathogen evolution,
where possible, to control the disease, the hygiene principle would
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Fig. 6. Immunity selects for higher levels of intrinsic virulence. In panel A, the solid line shows the ﬁtness curve for parasites as a function of observed (or realised) virulence
in naı¨ve hosts. In naı¨ve hosts, it is maximised at some intermediate virulence level, ˛* , as indicated by the symbol. However, if the parasite ﬁnds itself in a semi-immune
host, its ﬁtness is lower than maximal (vertical dotted line) because of its lower (by amount ) or observed virulence, hence the symbol. In panel B, the ﬁtness is shown
as a function of intrinsic virulence, i.e., that which would be observed in naı¨ve hosts. In naı¨ve hosts (solid line), ˛* is the optimal level of virulence, as in panel A. However,
in semi-immune hosts (dotted line), the optimal level of intrinsic virulence ﬁtness would be maximised at a higher level of virulence, viz. ˛* +. This is because its realised
virulence would be this value, less the effect of immunity, . But this optimal level of intrinsic virulence at ˛* + would be too high for a naı¨ve host (solid line), as indicated
by the symbol.
Fig. 7. Vaccines (or other control devices) can be targeted at different stages of the malaria parasite’s life cycle (panel A). r1-type devices block infection (e.g., a liver-stage
vaccine), r2-type devices act against replication (e.g., asexual-stage vaccines), r3-type devices act against transmission from the host (e.g., transmission-blocking vaccines
or bednets), and r4-type devices act directly against the toxicity of the pathogen (e.g., anti-toxin vaccine, or life-saving therapies). The consequences of virulence evolution
to unvaccinated hosts (top panel) and the total population of hosts (vaccinated, unvaccinated and naturally immune) are shown as a function of vaccine coverage (x-axis)
(panel B). The solid lines show the mortality expected if the pathogen evolves, and the dotted lines show the consequences if it does not. For an r2-type vaccine, virulence
evolution is expected to erode all the beneﬁts of vaccination and cause more death in unvaccinated individuals. In contrast, r1-type and r3-type devices are expected to
select for avirulence. Preventing death using an r4-type device selects for higher virulence in unvaccinated people, but is beneﬁcial to the overall population. The effect of a
combination vaccine is shown in the last column. Reproduced with permission from Gandon et al. [43].
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appear to be an excellent one to follow for evolutionary reasons as
well as for its more obvious epidemiological applications.
The theoretical conclusion that using devices that prevent infec-
tion or block transmission will lead to reduced virulence arises
because of the lower force of infection (transmission intensity from
the vector population) causedby the control programme. This leads
to lower levels of coinfection or superinfection and hence the lower
level of competition among parasites occupying the same host. The
reduced selection pressure for high virulence due to relaxation of
competition can be understood by taking the viewof a resident par-
asite that is either oustedby (superinfection) or forced to sharewith
(coinfection) another parasite type. In the case of superinfection,
the resident parasite has its infection shortened by the invading
parasite: the parasite then compensates by evolving a higher level
of host exploitation, or intrinsic virulence, up to the point when
the beneﬁts are balanced by the costs. This is especially so where
virulence is associated with competitive ability, as it is at least in
P. chabaudi (see Section 2.1). In the case of coinfection, the risk of
mortality for the resident parasite is increased by the presence of
another parasite, thus increasing the costs. Again, the parasite has
to compensate by increasing its level of host exploitation (beneﬁts).
The principles of superinfection and coinfection also extend to
co-morbidity from other infections. In malaria, concomitant infec-
tion with bacterial pathogens greatly enhances the probability of
dying in young children [53]. This higher ‘background mortality’ in
children is generally expected to heighten the selection pressure on
virulence [54,55] (but see [56]). Thus controllingotherdiseasesmay
also relieve the selection pressure on malaria virulence. Indeed,
as discussed above, a general principle that arises from the trade-
off model is that if external factors act to decrease the duration of
infection, then optimum virulence increases. These factors may be
related to host death (e.g., war, co-morbidity, andmosquitomortal-
ity), or to the rate of clearance of the infection (e.g., superinfection,
or drugs).
4. An experimental test of the vaccination theory
As we cannot test the vaccination hypothesis in the ﬁeld until it
is too late, we would ideally test it in the laboratory in mice or in
vitro. This could be done by evolving replicate parasite lines under
conditions of high vs. low immunity using their natural transmis-
sion system. However, it is extremely difﬁcult in the laboratory
to repeatedly transmit multiple parasite lines of malaria through
mosquitoes for the entire period of their transmissibility: it is also
ethically challenging to allow mouse death to act as the selecting
agent. Therefore we designed an experiment to test one compo-
nent of the vaccine hypothesis, namely, that immunity selects for
higher rates of host exploitation (regardless of the transmission
consequences). This was done by transferring a standard number
ofparasitesbetweenmiceevery7days for18passages, thusbypass-
ing the mosquito stage of the life cycle. At the end of this selection
phase, the replicated lineswere passaged once throughmosquitoes
and tested for virulence and other characteristics in either naı¨ve or
semi-immune mice. We found that parasite lines that had evolved
in immunised hosts were more virulent than parasite lines that
had evolved in naı¨ve hosts (Fig. 8). This was true whether the lines
were infecting naı¨ve or immunised mice, and whether or not the
lines had been passaged through mosquitoes prior to testing them
[22]. The immune-selected lines also had higher intrinsic replica-
tion rates than the naı¨ve-selected lines (Fig. 8). Thus immunity had
moreefﬁciently selected theparasiteswithgreater ability to exploit
the host and thus cause more virulence. This result is consistent
withour theory thatblood-stagevaccineswould select formorevir-
ulent parasites, but the mechanism of selection in this experimente 26S (2008) C42–C52 C49
was different to that we proposed for human malaria in the ﬁeld
becausewe did not allow themortality-induced transmission costs
to do the selecting. The results from this experiment nevertheless
support the underlying basis of the trade-off model, namely, that
replication rate is the parasite’s key to transmission success, espe-
cially in semi-immune hosts, with virulence being an unfortunate
side-effect.
Itwill be impossible to do adirect test of the vaccinationhypoth-
esis in human malaria before the uncontrolled experiment is done
on a vast scale. But there are two approaches that could be taken in
themeantime. First, one could examine the outcome of the natural
experiment that has been done. According to the theory, para-
sites from highly immune populations (naturally acquired) should
be intrinsically more virulent than parasites from less immune
populations. Thus a comparison of case fatality rates and disease
severity among naı¨ve individuals could be made from high trans-
mission intensity areas (where population immunity is high) and
from low transmission areas. There is some limited evidence to
support this argument [57,58], but see Reyburn et al. [59]. The
hypothesis could also be tested by comparing mortality rates of
malaria-naı¨ve travellers who have acquired their infection from
high vs. low transmission areas. A secondwaywould be to compare
in vitro the virulence-related molecular phenotypes of parasites
fromareaswith contrasting transmission intensities. Studies taking
both approaches are under way.
5. Vaccine-driven virulence evolution, and other diseases
One of the few large-scale malaria vaccine trials to date has
alreadydemonstrated vaccine-driven evolution [60]. TheCombina-
tion B asexual blood-stage vaccine consists of several blood-stage
antigens. During a phase II trial in Papua NewGuinea, it was shown
that vaccination reduced the prevalence of the allele of one of the
antigens used in the vaccine. The alternative allele, which was
not present in the vaccine and which rose in frequency, had in
previous studies been associated with more virulent infections
[61].
In principle, a variety of different types of mutants could evolve
in response to vaccination [62]. These could include antigenic vari-
ants that are less readily recognised by vaccine-induced immunity
thus giving rise to ‘serotype replacement’ [63–65]. However, there
is no a priori reason to think such antigenic escape variants will
have lower or higher intrinsic virulence than the one targeted by
the vaccine. In this paper, however, we have argued that there exist
variants that have a ﬁtness advantage in semi-immune hosts inde-
pendent of antigenic type, e.g., due to higher intrinsic growth rate.
In the absence of vaccination, these variants are selected against
because of their excessive virulence in naı¨ve hosts, but are favoured
in vaccinatedpopulationswhere they areprotected fromtheﬁtness
costs of host death. Thus such variants could have changes at anti-
gen loci, and these may or may not affect replication rate, but they
could also include loci other than those encoding antigens, such as
genesencoding replication rate, toxinproduction, and immunosup-
pressive compounds, and these have the potential to confer great
virulence. Formalaria,we donot have a clear ideawhich are the vir-
ulence genes, whether they confer intrinsically higher virulence or
just immune escape and thereforewhat the effects a particular vac-
cine might have on virulence evolution. But our arguments above,
combined with our experimental evolution results (Fig. 8) and the
experience of the combination B vaccine [60] suggest that what-
ever the mechanism, we should consider in advance the possible
evolutionary outcomes of imperfect interventions.
Are there any examples in other pathogens where vaccines
have driven the pathogen towards higher virulence? Vaccines
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against smallpox, measles and polio have been outstandingly
successful. These vaccines induce near-sterilising immunity. On
the other hand, for diseases where vaccines are leaky, so that
wild-type pathogens transmit and thus evolve through immune
people, changes in pathogen virulence following vaccination have
been documented, such as diphtheria, pneumococcal disease and
whooping cough (pertussis). These cases have been discussed in
more detail elsewhere ([62,66]; Gandon and Day, this issue). While
these examples demonstrate that pathogen evolution in response
to vaccines can happen, the effects on virulence are extremely
difﬁcult to determine because comparisons of virulence are very
difﬁcult without contemporaneous experimental infections with
the different pathogen strains. For many animal diseases, where
such experiments can be done, successful vaccines are frequently
leaky. There are clear examples from the poultry industry of
substantial increases in virulence following the widespread intro-ve (N-lines) mice. Starting with an avirulent clone, ﬁve independent parasite lines
the experimental design). At the end, the lines were passaged through mosquitoes
sity reached during the infection), the rate of population growth during the ﬁrst 6
proportion of infected red blood cells that bind to more than two uninfected cells
stently associated with virulence [85–88]). Heights of bars represent means (with
ection treatment. Selection in immunised mice generated more virulent parasites
uring within-host selection. These differences were present in the lines both before
he evolved difference was genetically stable. These parasites also multiplied faster
nd a strong immune response. This difference was not apparent in the lines before
per day [23]) having been reached. Rosetting was also the same in the two sets of
irection to that expected from human malaria, i.e., it was lower in the most virulent
ree traits (virulence, P<0.05; multiplication rate, P<0.001; rosetting, P<0.05). Data
duction of vaccines to both Marek’s disease and Infectious Bursal
Disease (reviewed in [66]). These cases have all the hallmarks of
vaccine-driven generalised virulence evolution. However, exper-
imental analysis of their V–T–P relationships is still required to
determine whether vaccination was indeed the cause. The sub-
sequent history of the myxoma virus evolution demonstrates the
role host resistance can also play in driving virulence evolution. As
wild rabbits evolved greater resistance to myxomatosis, the virus
evolved greater virulence (reviewed by [66,67]).
Many new generation vaccines against human diseases are, like
candidate malaria vaccines, very likely to be substantially leaky
because natural immunity against their causative pathogens is far
from perfect, or the pathogen has good mechanisms for immune
evasion or suppression (e.g., HIV, Hepatitis B and C). In diseases
for which the V–T–P relationships are as they are in myxomato-
sis (Fig. 2) and rodent malaria (Fig. 3), we expect our argument to
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apply wherever imperfect vaccines are in widespread use. For dis-
eases where the V–T–P relationships are qualitatively different to
those described above, vaccines could produce other evolutionary
outcomes (e.g., [51]).
The current situation is, however, that for most human diseases
we simply do not know the V–T–P relationships: indeed, in our
view, much of the controversy surrounding the trade-off model
[68–73] arises because of the lack of direct experimentation on
medically relevant diseases. In the molecular era, it is now feasible
for many disease systems to properly quantify pathogen trans-
mission and persistence for individual infections for the range of
circulating pathogen genotypes. Because of the variability in viru-
lence and transmissibility during the infection, this is ideally done
for the full course of the infection. For example, of key importance
is the time at which host mortality occurs in relation to when the
bulk of transmission occurs. If death occurs early in the infection
(e.g., in malaria where transmission does not occur until after the
most dangerous point in the infection), then loss of transmission
is high and so the cost relative to the beneﬁt is high: if it occurs
late (e.g., in HIV or tuberculosis), much of the transmission has
already occurred prior to host death, and the costs are relatively
lower [74]. Thus these pathogens can “afford” higher mortality
rates. Such considerations, and others such as the role of immu-
nity, and other in-host limitations in generating the trade-off curve
[44,49,75–79], highlight the importance of understanding within-
host dynamics to properly evaluate the V–T–P relationships in both
acute and chronic infections. This is an area we have so far paid lit-
tle attention to in malaria, but we believe is one that is likely to
be useful for properly quantifying the ﬁtness beneﬁts and costs of
virulence in humanmalaria, and hence evaluating the applicability
of the trade-off model to this disease.
6. Conclusions
In the case ofmalaria, forwhich a vaccine is not yet available but
is being intensively pursued, we have presented the case for why
virulence may evolve in response to vaccines, what we might do to
avoid it, andwhatwe further need to do to determine its likelihood.
Key points are:
• In rodent malaria, virulence, transmissibility and persistence
appear to be intrinsically linked through the parasite’s biol-
ogy/life history, and these links are maintained over different
levels of host immunity. We are unaware of any data on human
malaria which contradicts this picture, though ﬁeld and clini-
cal data are necessarily more ambiguous. Immunity has a very
strong impact on parasite ﬁtness through its effect on reducing
all threeV–T–P traits inaccordancewith theirbiological links, and
by reducing host death and hence the ﬁtness cost of virulence.
• Our simple models, informed and parameterised from exper-
imental work on rodent malaria and from human ﬁeld data,
predict that interventions that reduce asexual density but do not
block infection, such as anti-asexual-stage vaccines, and drugs,
are expected to lead to evolution of higher virulence, while
hygiene (i.e., preventing infection and transmission) is expected
to lead to evolution of lower virulence.
• More data are required in human malaria to determine whether
the V–T–P relationships are encoded by parasite genes, and
to determine how much virulence variation exists in the ﬁeld.
Tests of the immunity-virulence evolution hypothesis in human
malaria, where possible, are urgently required. Better knowledge
of the contributions to transmission by adults and childrenwould
help identify themost important source of selection pressure and
hence help direct age-targeted interventions.
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• Meanwhile, a cautionary approach to the widespread use of
anti-replication or anti-disease vaccines seems justiﬁed. Ideally,
this means combining such vaccines with transmission-blocking
vaccines, bednets, drugs, housing improvements and other
transmission-reducing measures. If a plurality of approaches is
not possible, we urge long term monitoring of virulence trends,
and the continual development of alternative anti-malarial mea-
sures. The history of malaria control is one of continual failure in
the face of evolution.
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